FindTrial
Sign In

RP3

BIOLOGICAL4 trials

Sponsors

Replimune Group Inc., Replimune Inc.

Conditions

Advanced Solid TumorAdvanced solid tumorsHepatocellular CarcinomaLocally Advanced Head and Neck Squamous Cell CarcinomaMSSMelanomaMetastatic MelanomaRecurrent Head and Neck Squamous Cell Carcinoma

Phase 1

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Active, not recruitingNCT04735978
Replimune Inc.Advanced Solid Tumor
Start: 2020-12-29End: 2026-11-30Target: 123Updated: 2026-02-27

Phase 2

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
TerminatedNCT05733611
Replimune Inc.MSS, pMMR, Refractory Metastatic Colorectal Cancer
Start: 2023-06-29End: 2025-08-18Updated: 2026-02-02
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
WithdrawnNCT05743270
Replimune Inc.Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Start: 2024-01-30End: 2026-06-01Updated: 2025-03-11

Phase 4

Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
Not yet recruitingCTIS2025-521621-33-00
Replimune Group Inc.Advanced solid tumors, Hepatocellular Carcinoma, Melanoma +1
Target: 13Updated: 2026-02-09

Related Papers

An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma.
Journal of Clinical Oncology2024-01-202 citations
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
Journal of Clinical Oncology2023-06-012 citations
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.
Journal of Clinical Oncology2023-06-011 citations
Abstract 6639: Preclinical characterization and clinical biomarker studies with RP3, a novel oncolytic immunotherapy expressing a fusogenic protein, a human anti-CTLA-4 antibody, hCD40L and h4-1BBL
Cancer Research2023-04-04
575 Safety and feasibility of intratumoral injection of the RPx family of oncolytic immunotherapies in patients with liver metastasis
Regular and Young Investigator Award Abstracts2022-11-01
An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors.
Journal of Clinical Oncology2022-06-013 citations